SCYNEXIS wins BARDA contract worth up to $214 million for SCY-247 development

Bitget2026/09/28 11:31

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

SCYNEXIS won a BARDA contract worth up to USD 214 million to fund development of its SCY-247 antifungal through potential NDA submissions.
Base period provides USD 18.5 million to move oral and IV SCY-247 into a Phase 2 trial for invasive candidiasis.
Contract includes an option to support a second indication focused on prevention in high-risk patients; term can extend up to 10 years.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SCYNEXIS Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609280730PRIMZONEFULLFEED9834679) on September 28, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

SCYNEXIS wins BARDA contract worth up to $214 million for SCY-247 development

You may also like

Crypto prices